skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Clinical development of 1% azithromycin in DuraSite®, a topical azalide anti-infective for ocular surface therapy

(2723) Views  (930) Full article downloads

Authors: Mitchell H Friedlaender, Eugene Protzko

Published Date June 2007 Volume 2007:1(1) Pages 3 - 10
DOI: http://dx.doi.org/10.2147/OPTH.S

Mitchell H Friedlaender1, Eugene Protzko2

1Division of Ophthalmology, Scripps Research Institute, Refractive Surgery Program, Scripps Clinic, La Jolla, CA, USA; 2Seidenberg Protzko Eye Associates, Havre De Grace, MD, USA

Abstract: Conjunctivitis, or inflammation of the conjunctiva, refers to a diverse group of ocular surface diseases of viral or bacterial origin that primarily affect the conjunctiva. In developed countries, the most common causative bacterial pathogens are Staphylococcus aureus, Haemophilus influenzae, and Streptococcus pneumoniae. Most varieties of conjunctivitis are self-limiting; however, some cases can be extremely contagious or cause serious complications if left unchecked. New ocular antibiotics are needed to keep pace with the increasing incidence of bacterial resistance and provide options that decrease the overall treatment burden and encourage patient compliance. Azithromycin is a well known systemic anti-infective with broad spectrum activity against gram positive-, gram negative-, and atypical bacteria species. Ocular use has been limited because its solubility and stability profiles in aqueous media were not favorable for delivery to the eye. An eyedrop of 1% azithromycin in DuraSite® (AzaSite™, InSite Vision, Alameda, CA, USA), a bioadhesive ocular drug delivery system, was recently developed and evaluated in clinical trials. This formulation is well tolerated, delivers a high concentration of azithromycin to the conjunctiva, has a broader eradication profile than aqueous azithromycin, and can be effectively dosed with 7 drops, a 65% reduction in the amount of drops required by the most popular antibiotics currently used for conjunctivitis.

Keywords: anti-infective, ocular surface, conjunctiva, clinical trial, drug-delivery, azalide








Readers of this article also read:

Effect of proinflammatory cytokines on the human MUC5AC promoter activity in vitro and in vivo
Indications and clinical outcome of capsular tension ring (CTR) implantation: A review of 9528 cataract surgeries
Randomized trial of superficial peribulbar compared with conventional peribulbar anesthesia for cataract extraction
A randomized trial assessing the clinical efficacy and microbial eradication of 1% azithromycin ophthalmic solution vs tobramycin in adult and pediatric subjects with bacterial conjunctivitis
Fluoroquinolones compared to 1% azithromycin in DuraSite® for bacterial conjunctivitis [from Lichenstein and Granet] and Response to correspondence [from Friedlaender and Protzko] ||FREE PAPER||
Editorial
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
Corrigendum
Erratum
A case of recurrent bloody tears